F Rosenow1, A Kelemen2, E Ben-Menachem3, C McShea4, J Isojarvi4, P Doty4. 1. Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, Goethe University, Frankfurt a. M, Germany. 2. National Institute of Neurosciences, Budapest, Hungary. 3. Institute of Clinical Neurosciences, Division of Neurology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 4. UCB Pharma, Raleigh, NC, USA.
Abstract
OBJECTIVE: To evaluate long-term (up to 5.5 years) safety, seizure reduction, and maintenance of efficacy of the antiepileptic drug (AED) lacosamide as adjunctive treatment in an open-label extension trial (SP774; ClinicalTrials.gov: NCT00515619). METHODS:Three hundred and seventy-six adults with partial-onset seizures taking 1-3 AEDs enrolled following completion of a double-blind trial ofadjunctive lacosamide. During open-label treatment, dosage of lacosamide (100-800 mg/day) and/or concomitant AEDs could be adjusted to optimize tolerability and seizure control. RESULTS: Kaplan-Meier estimates of patient retention were 74.5% at 12 months, 52.9% at 36 months, and 40.6% at 60 months; median open-label treatment duration was 1183 days (~3.2 years). The most frequently reported treatment-emergent adverse events were dizziness (24.2%), headache (14.4%), diplopia (13.8%), and nasopharyngitis (13.8%); 9.0% of patients discontinued due to adverse events, most commonly dizziness (1.3%). Median percent reduction in 28-day seizure frequency from baseline of the double-blind trial was 49.9% overall, 55.4% for 1-year completers, and 62.3% for 3-year completers. Overall, 50.0% of patients were considered ≥50% responders (achieved ≥50% reduction in 28-day seizure frequency); 55.9% of 1-year completers and 63.0% of 3-year completers were ≥50% responders. CONCLUSION: In eligible patients who entered the open-label extension trial, lacosamide was generally well tolerated. For most patients within each yearly completer cohort, seizure reduction was maintained over time.
RCT Entities:
OBJECTIVE: To evaluate long-term (up to 5.5 years) safety, seizure reduction, and maintenance of efficacy of the antiepileptic drug (AED) lacosamide as adjunctive treatment in an open-label extension trial (SP774; ClinicalTrials.gov: NCT00515619). METHODS: Three hundred and seventy-six adults with partial-onset seizures taking 1-3 AEDs enrolled following completion of a double-blind trial of adjunctive lacosamide. During open-label treatment, dosage of lacosamide (100-800 mg/day) and/or concomitant AEDs could be adjusted to optimize tolerability and seizure control. RESULTS: Kaplan-Meier estimates of patient retention were 74.5% at 12 months, 52.9% at 36 months, and 40.6% at 60 months; median open-label treatment duration was 1183 days (~3.2 years). The most frequently reported treatment-emergent adverse events were dizziness (24.2%), headache (14.4%), diplopia (13.8%), and nasopharyngitis (13.8%); 9.0% of patients discontinued due to adverse events, most commonly dizziness (1.3%). Median percent reduction in 28-day seizure frequency from baseline of the double-blind trial was 49.9% overall, 55.4% for 1-year completers, and 62.3% for 3-year completers. Overall, 50.0% of patients were considered ≥50% responders (achieved ≥50% reduction in 28-day seizure frequency); 55.9% of 1-year completers and 63.0% of 3-year completers were ≥50% responders. CONCLUSION: In eligible patients who entered the open-label extension trial, lacosamide was generally well tolerated. For most patients within each yearly completer cohort, seizure reduction was maintained over time.
Authors: Sebastian Bauer; Laurent M Willems; Esther Paule; Christine Petschow; Johann Philipp Zöllner; Felix Rosenow; Adam Strzelczyk Journal: Ther Adv Neurol Disord Date: 2016-11-29 Impact factor: 6.570
Authors: Josemir W Sander; William E Rosenfeld; Jonathan J Halford; Bernhard J Steinhoff; Victor Biton; Manuel Toledo Journal: Epilepsia Date: 2021-11-23 Impact factor: 6.740
Authors: V Villanueva; B G Giráldez; M Toledo; G J De Haan; E Cumbo; A Gambardella; M De Backer; L Joeres; M Brunnert; P Dedeken; J Serratosa Journal: Acta Neurol Scand Date: 2018-03-14 Impact factor: 3.209
Authors: Elinor Ben-Menachem; Hans Peter Grebe; Kiyohito Terada; Lori Jensen; Ting Li; Marc De Backer; Björn Steiniger-Brach; Teresa Gasalla; Melissa Brock; Victor Biton Journal: Epilepsia Date: 2019-11-21 Impact factor: 5.864
Authors: Jacqueline A French; Steve S Chung; Gregory L Krauss; Sang Kun Lee; Maciej Maciejowski; William E Rosenfeld; Michael R Sperling; Marc Kamin Journal: Epilepsia Date: 2021-07-13 Impact factor: 5.864